VANCOUVER, British Columbia, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to announce the launch of 1964 Supply Co.™ (“1964”) full spectrum vapes in the United Kingdom through its distribution partnership with 4C LABS.

“The response to 1964 in the U.K. has demonstrated that there is growing demand for premium medical cannabis products in international markets,” said Margaret Brodie, Chief Executive Officer of Rubicon Organics. “With patient numbers in the U.K. expected to grow 40% this year¹, and vape offerings increasingly popular, the launch of 1964 full spectrum vapes builds on the success of the brand in the U.K. and further strengthens our position in a rapidly expanding market.”

1964 first entered the U.K. market with its award-winning Blue Dream and Stinky Pinky flower strains in April. Rubicon Organics has since expanded the brand's flower offerings to include its Apples and Bananas flower, and the launch of full spectrum vapes marks the next step in developing the 1964 portfolio for the U.K. medical cannabis market. By extending its premium genetics into vape formats, 1964 provides patients with additional consumption options beyond flower while maintaining the quality, consistency, and cultivar-driven experience associated with the brand.

1964 is one of Rubicon Organics’ flagship brands and one of Canada’s leading premium cannabis brands, having won numerous awards including Brand of the Year for the last two years at the industry’s prestigious KIND Awards. The brand is inspired by classic legacy genetics and designed to deliver genuine, high-quality cannabis with a focus on consistency and trust.

ABOUT RUBICON ORGANICS INC.

Rubicon Organics is the Canadian leader in certified organic and premium cannabis. With a vertically integrated model and strong national distribution, the company is scaling a house of trusted, high-performing brands including Simply Bare™ Organic, 1964 Supply Co.™, Wildflower™, and Homestead Cannabis Supply™.

The Company operates two complementary cultivation facilities in British Columbia: the flagship 125,000 square foot Pacifica hybrid greenhouse in Delta and the 47,500 square foot Cascadia indoor facility in Hope. Cascadia is now fully planted and operational, contributing to Rubicon’s total current annual production capacity of approximately 15,500 kilograms of premium cannabis.

With proprietary genetics, award-winning products, and certifications enabling international distribution, Rubicon is positioned at the forefront of the premium cannabis segment.

As the Canadian market continues to evolve and global demand for high-quality cannabis increases, Rubicon Organics’ disciplined execution, brand equity, and consumer loyalty set it apart. The Company’s continued focus on premium quality, thoughtful innovation, and operational excellence has supported steady revenue growth and positive Adjusted EBITDA.

Rubicon Organics represents a rare combination of category leadership, operational strength, and long-term growth potential.

For more information visit www.rubiconorganics.com.

ABOUT 4C LABS

4C LABS Ltd. is a privately held Canadian medical cannabis company focusing on providing pharmacies & clinics with world class medical cannabis products at an affordable price. 4C LABS has import and distribution licenses in the UK and a wide network of pharmacies in the UK & Channel Islands. 4C LABS carries a full product line of medical cannabis from a selected network of trusted international cultivation partners. For more information, please visit www.4clabs.co.

CONTACT INFORMATION

Margaret Brodie
CEO
Phone: +1 (437) 929-1964
Email: ir@rubiconorganics.com

The TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”. Forward-looking information can be identified by the use of words such as “will” or variations of such words or statements that certain actions, events or results “will” be taken, occur or be achieved.

Forward-looking information is based on management's current expectations, estimates, projections and assumptions as of the date of this press release, including, without limitation, assumptions regarding continued patient demand for premium medical cannabis products; the continued availability of regulatory approvals and import permits; the ability of 4C LABS and other third parties to distribute the Company's products; stable market conditions; the Company's ability to maintain product quality, supply and production levels; and the Company's ability to successfully execute its business and international expansion strategies.

Forward-looking information in this press release includes, without limitation, statements regarding the Company's international growth strategy; the expansion and development of the 1964 Supply Co.™ portfolio in the United Kingdom; the availability, distribution and commercial performance of the Company's products in the U.K. medical cannabis market; demand for premium medical cannabis products in international markets; the continuation and success of the Company's distribution partnership with 4C LABS; the Company's ability to expand its presence in regulated international markets; the expected benefits of new product launches; and the Company's production capacity, revenue growth opportunities and strategic initiatives.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, among others, the risk that anticipated production, yield, operational efficiency, revenue, margin or profitability targets are not achieved; changes in market conditions, consumer demand, and competition; changes in laws, regulations and regulatory policies governing medical cannabis in Canada, the United Kingdom and other international markets; reliance on third-party distributors and service providers; pricing pressures; product recalls; supply chain disruptions; foreign exchange fluctuations; challenges in maintaining required certifications and quality standards; access to capital; and the other risk factors described under the heading “Risk Factors” in Rubicon Organics’ Annual Information Form dated March 23, 2026, filed with the Canadian securities regulatory authorities.

Readers are cautioned not to place undue reliance on forward-looking statements. Although the Company believes that the expectations and assumptions underlying such statements are reasonable, there can be no assurance that they will prove to be accurate, and actual results and future events may differ materially from those anticipated. Except as required by applicable law, Rubicon Organics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

¹ Prohibition Partners, UK Medical Cannabis Market Update 2026 (June 2026)